Markets forgive Q4 miss for a healthy 2026 outlook
25/02/26 -"Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy growth in both the Surgical and Vision Care segments. ..."
Pages
50
Language
English
Published on
25/02/26
You may also be interested by these reports :
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...
23/02/26
Considering the lower medium-to-long-term expectations, the premium for peer-based metrics has been reduced to 25% (vs. 50% previously). However, ...